MA33469B1 - Polythérapie à base d'un anticorps afucosylé anti-cd20 et de bendamustine - Google Patents

Polythérapie à base d'un anticorps afucosylé anti-cd20 et de bendamustine

Info

Publication number
MA33469B1
MA33469B1 MA34585A MA34585A MA33469B1 MA 33469 B1 MA33469 B1 MA 33469B1 MA 34585 A MA34585 A MA 34585A MA 34585 A MA34585 A MA 34585A MA 33469 B1 MA33469 B1 MA 33469B1
Authority
MA
Morocco
Prior art keywords
polytherapy
antibody
bendamustin
afucosylated anti
afucosylated
Prior art date
Application number
MA34585A
Other languages
Arabic (ar)
English (en)
Inventor
Frank Herting
Christian Klein
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41351729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33469(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA33469B1 publication Critical patent/MA33469B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Abstract

Cette invention concerne une polythérapie à base d'un anticorps afucosylé anti-CD20 et de bendamustine pour le traitement du cancer, et notamment, la polythérapie des cancers exprimant CD20 à base d'un anticorps afucosylé anti-B-Ly1 humanisé et de bendamustine.
MA34585A 2009-08-14 2010-08-12 Polythérapie à base d'un anticorps afucosylé anti-cd20 et de bendamustine MA33469B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09010489 2009-08-14
PCT/EP2010/004939 WO2011018224A1 (fr) 2009-08-14 2010-08-12 Polythérapie à base d'un anticorps afucosylé anti-cd20 et de bendamustine

Publications (1)

Publication Number Publication Date
MA33469B1 true MA33469B1 (fr) 2012-07-03

Family

ID=41351729

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34585A MA33469B1 (fr) 2009-08-14 2010-08-12 Polythérapie à base d'un anticorps afucosylé anti-cd20 et de bendamustine

Country Status (34)

Country Link
US (4) US20110165151A1 (fr)
EP (1) EP2464382B1 (fr)
JP (3) JP5646626B2 (fr)
KR (1) KR101425736B1 (fr)
CN (2) CN107261138A (fr)
AR (1) AR077866A1 (fr)
AU (1) AU2010281866B2 (fr)
BR (1) BR112012002855A2 (fr)
CA (1) CA2769674C (fr)
CL (1) CL2012000391A1 (fr)
CR (1) CR20120036A (fr)
CY (2) CY1119251T1 (fr)
DK (1) DK2464382T3 (fr)
ES (1) ES2630158T3 (fr)
HK (1) HK1245145A1 (fr)
HR (1) HRP20170972T1 (fr)
HU (2) HUE033531T2 (fr)
IL (1) IL217753A (fr)
LT (2) LT2464382T (fr)
LU (1) LUC00045I2 (fr)
MA (1) MA33469B1 (fr)
MX (2) MX355849B (fr)
MY (1) MY163003A (fr)
NO (1) NO2017054I1 (fr)
NZ (1) NZ597666A (fr)
PL (1) PL2464382T3 (fr)
PT (1) PT2464382T (fr)
RS (1) RS56146B1 (fr)
SG (1) SG178324A1 (fr)
SI (1) SI2464382T1 (fr)
TW (1) TWI409079B (fr)
UA (1) UA110096C2 (fr)
WO (1) WO2011018224A1 (fr)
ZA (1) ZA201200830B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS55723B1 (sr) 2003-11-05 2017-07-31 Roche Glycart Ag Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
CA2692819A1 (fr) 2007-07-16 2009-01-22 Genentech, Inc. Anticorps anti-cd79b humanises, immunoconjugues, et procedes d'utilisation
PE20140614A1 (es) 2007-07-16 2014-05-28 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
SI2247620T1 (sl) 2008-01-31 2016-09-30 Genentech, Inc. Protitelesa proti CD79b in imunokonjugati in postopki za uporabo
RS55184B1 (sr) 2010-05-31 2017-01-31 Ono Pharmaceutical Co Derivat purinona kao inhibitor btk kinaze
FR2976811A1 (fr) * 2011-06-22 2012-12-28 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
EP4083071A3 (fr) * 2011-08-16 2023-02-22 MorphoSys AG Thérapie combinée d'un anticorps anti-cd19 avec un analogue de purine
KR20200058583A (ko) * 2011-08-16 2020-05-27 모르포시스 아게 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
FR2980110A1 (fr) * 2011-09-20 2013-03-22 Lfb Biotechnologies Combinaison d'anticorps anti-cd20 et de bendamustine
HUE031094T2 (en) 2011-11-29 2017-07-28 Ono Pharmaceutical Co Purinone derivative hydrochloride
CN103375132A (zh) * 2012-04-24 2013-10-30 长江大学 井下旋转冲击式钻井工具
EP2762496A1 (fr) 2013-02-05 2014-08-06 EngMab AG Procédé pour la sélection d'anticorps contre BCMA
PL2953972T3 (pl) 2013-02-05 2021-03-08 Engmab Sàrl Metoda wyboru przeciwciał przeciwko bcma
KR102033819B1 (ko) * 2013-06-07 2019-10-17 노르딕 나노벡터 에이에스에이 상향조절 항원 발현 방법
ES2806506T3 (es) 2014-03-25 2021-02-17 Ono Pharmaceutical Co Agente profiláctico y/o agente terapéutico para el linfoma difuso de células B grandes
EP3689910A3 (fr) 2014-09-23 2020-12-02 F. Hoffmann-La Roche AG Procédé d'utilisation d'immunoconjugués anti-cd79b
EP3281943B1 (fr) 2015-04-09 2023-06-28 ONO Pharmaceutical Co., Ltd. Procédé de fabrication d'un dérivé de purinone
KR20180042271A (ko) 2015-08-03 2018-04-25 잉맵 에스에이알엘 Bcma에 대응하는 단일클론 항체
EP3257866A1 (fr) * 2016-06-17 2017-12-20 Academisch Medisch Centrum Anticorps anti-tnf modifiés et leur utilisation dans le traitement de la maladie intestinale inflammatoire
MX2019004621A (es) 2016-11-02 2019-11-28 Engmab Sarl Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple.
WO2018106959A1 (fr) 2016-12-07 2018-06-14 Progenity Inc. Procédés, dispositifs et systèmes de détection du tractus gastro-intestinal
EP4108183A1 (fr) 2017-03-30 2022-12-28 Biora Therapeutics, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un agent immunomodulateur libéré à l'aide d'un dispositif ingérable
CN112399848A (zh) 2018-05-23 2021-02-23 细胞基因公司 用于组合使用的抗增殖化合物和针对bcma和cd3的双特异性抗体
WO2019246317A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie ou d'un état dans un tissu provenant de l'endoderme
WO2019246312A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un immunomodulateur
WO2020106757A1 (fr) 2018-11-19 2020-05-28 Progenity, Inc. Dispositif ingérable pour administrer un agent thérapeutique au tube digestif
JP7287048B2 (ja) 2019-03-27 2023-06-06 セイコーエプソン株式会社 ロボット
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
CA2332331A1 (fr) 1998-05-15 1999-11-25 Francisco Robert Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissance
PT1914244E (pt) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1443961B1 (fr) 2001-10-25 2009-05-06 Genentech, Inc. Compositions de glycoproteine
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP2330130B1 (fr) 2002-10-17 2014-08-27 Genmab A/S Anticorps monoclonaux humains contre le CD20
EP1572744B1 (fr) 2002-12-16 2010-06-09 Genentech, Inc. Variants d'immunoglobuline et utilisations
NZ541503A (en) 2003-01-22 2008-09-26 Glycart Biotechnology Ag Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
JP2006528697A (ja) * 2003-05-16 2006-12-21 イデラ ファーマシューティカルズ インコーポレイテッド イムノマーを化学療法剤と組み合わせて用いる、癌の相乗的処置
EP1648511A1 (fr) 2003-07-29 2006-04-26 Morphotek, Inc. Anticorps et procedes permettant de produire des anticorps genetiquement modifies presentant une fonction effectrice amelioree
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
WO2005027966A2 (fr) 2003-09-05 2005-03-31 Genentech, Inc. Anticorps aux fonctions d'effecteur modifiees
RS55723B1 (sr) * 2003-11-05 2017-07-31 Roche Glycart Ag Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
WO2005103081A2 (fr) 2004-04-20 2005-11-03 Genmab A/S Anticorps monoclonaux humains diriges contre cd20
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
JP5315489B2 (ja) 2005-04-26 2013-10-16 アール クレア アンド カンパニー エフェクター機能が増強されたヒトＩｇＧ抗体を作製する方法
CN101291954B (zh) 2005-08-26 2013-03-27 罗氏格黎卡特股份公司 具有改变的细胞信号传导活性的修饰的抗原结合分子
AU2006304886B2 (en) * 2005-10-21 2012-04-12 Genzyme Corporation Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US20090110688A1 (en) * 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
US8802089B2 (en) * 2008-01-03 2014-08-12 Genmab A/S Monoclonal antibodies against CD32B
CA2749151A1 (fr) * 2009-01-16 2010-07-22 Glaxosmithkline Llc Nouvelles utilisations
WO2010120288A1 (fr) * 2009-04-15 2010-10-21 Invista Technologies S.A R.L. Procédé d'amélioration de la miscibilité de composés par ailleurs non miscibles

Also Published As

Publication number Publication date
IL217753A0 (en) 2012-03-29
US20120315268A1 (en) 2012-12-13
ZA201200830B (en) 2012-10-31
CY1119251T1 (el) 2018-02-14
DK2464382T3 (en) 2017-07-17
WO2011018224A1 (fr) 2011-02-17
AU2010281866B2 (en) 2016-05-12
UA110096C2 (uk) 2015-11-25
PL2464382T3 (pl) 2017-09-29
NZ597666A (en) 2013-10-25
US20150093376A1 (en) 2015-04-02
CN102596245A (zh) 2012-07-18
KR101425736B1 (ko) 2014-08-01
MX2012001782A (es) 2012-04-19
LTPA2017035I1 (lt) 2017-11-27
HUE033531T2 (hu) 2021-12-28
MX355849B (es) 2018-05-02
CL2012000391A1 (es) 2012-08-24
ES2630158T3 (es) 2017-08-18
KR20120054068A (ko) 2012-05-29
BR112012002855A2 (pt) 2016-11-01
TWI409079B (zh) 2013-09-21
HUS000498I2 (hu) 2021-03-29
NO2017054I1 (no) 2017-10-26
JP5646626B2 (ja) 2014-12-24
SI2464382T1 (sl) 2017-08-31
US20110165151A1 (en) 2011-07-07
CA2769674C (fr) 2018-01-23
JP2015071611A (ja) 2015-04-16
RU2012109445A (ru) 2013-09-27
HUS1700041I1 (hu) 2017-11-28
MY163003A (en) 2017-07-31
EP2464382B1 (fr) 2017-05-03
EP2464382A1 (fr) 2012-06-20
CN107261138A (zh) 2017-10-20
US20160166688A9 (en) 2016-06-16
LUC00045I1 (fr) 2017-11-03
SG178324A1 (en) 2012-03-29
CY2017034I2 (el) 2018-02-14
US20140044705A1 (en) 2014-02-13
AU2010281866A1 (en) 2012-02-02
CA2769674A1 (fr) 2011-02-17
HK1245145A1 (zh) 2018-08-24
CR20120036A (es) 2012-04-18
JP2013501740A (ja) 2013-01-17
RS56146B1 (sr) 2017-11-30
LT2464382T (lt) 2017-07-25
AR077866A1 (es) 2011-09-28
JP5963013B2 (ja) 2016-08-03
HRP20170972T1 (hr) 2017-09-22
CY2017034I1 (el) 2018-02-14
LUC00045I2 (fr) 2018-02-26
IL217753A (en) 2016-10-31
TW201110980A (en) 2011-04-01
PT2464382T (pt) 2017-06-30
JP2016222673A (ja) 2016-12-28

Similar Documents

Publication Publication Date Title
MA33469B1 (fr) Polythérapie à base d'un anticorps afucosylé anti-cd20 et de bendamustine
MA33470B1 (fr) Polythérapie à base d'un anticorps afucosylé anti-cd20 et de fludarabine et/ou mitoxantrone
MA44645B1 (fr) Traitement combiné d'un anticorps anti-cd20 avec un inhibiteur de bcl-2 et un inhibiteur de mdm2
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
MY163521A (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
MA32748B1 (fr) Traitement du cancer de l'utérus du cancer de l'ovaire avec un inhibiteur parp utilisé seul ou en combinaison avec des antitumoraux
PA8851101A1 (es) Compuesto amino pirazol
MX2020010639A (es) Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer.
MX2015013203A (es) Conjugados de anticuerpo - farmaco.
MA35210B1 (fr) Polythérapie comportant un inhibiteur de cdk4/6 et un inhibiteur de pi3k à utiliser dans le traitement du cancer
MA31984B1 (fr) Formulation d'anticorps
EA201590866A1 (ru) Комбинация анти-cd20 антитела и селективного ингибитора киназы pi3
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MA34059B1 (fr) Thérapie anti-angiogénique pour le traitement du cancer des ovaires
MX2010004164A (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un inhibidor de proteasoma.
FR2975600B1 (fr) Agents pour le traitement de tumeurs
FR2942798B1 (fr) Peptides utilisables pour le traitement de la leucemie lymphoide chronique
MA31265B1 (fr) Traitement du cancer au moyen de l'il-18 humaine combinee a un anticorps anti-cd20
MA35173B1 (fr) Anticorps anti-cxcr4 ayant des fonctions effectrices et son utilisation pour le traitement du cancer
MA53069B1 (fr) Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer
MX347463B (es) Terapia de combinación de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf.
MA34827B1 (fr) Protéine hybrides robo1-fc à utiliser dans traitement d'hépatocarcinomes
AR081321A1 (es) N-cadherina: un blanco para el diagnostico y la terapia del cancer
UA109148C2 (uk) Композиції на основі антитіла проти vegfr-3
MA37475A1 (fr) Biomarqueurs pour thérapie par inhibiteur de iap